Genetic Technologies Ltd.
GENE Real Time Price USDRecent trades of GENE by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by GENE's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Methods of assessing risk of developing a severe response to coronavirus infection Feb. 22, 2022
-
Patent Title: Methods for breast cancer risk assessment Jul. 27, 2021
-
Patent Title: Computer systems and methods for genomic analysis Jun. 08, 2021
-
Patent Title: Method for modifying a treatment regimen of a human female subject Feb. 16, 2021
-
Patent Title: Methods for assessing risk of developing breast cancer Jun. 16, 2020
-
Patent Title: Methods for obtaining fetal genetic material Sep. 20, 2016
-
Patent Title: Biological sampling device Jul. 14, 2015
-
Patent Title: Biological sampling device Sep. 09, 2014
-
Patent Title: Device and method for obtaining a biological sample May. 27, 2014
-
Patent Title: Identification of fetal dna and fetal cell markers in maternal plasma or serum Mar. 12, 2013
-
Patent Title: Methods of genetic analysis involving the amplification of complementary duplicons Nov. 20, 2012
-
Patent Title: Maternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood Aug. 31, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of GENE in WallStreetBets Daily Discussion
Recent insights relating to GENE
Recent picks made for GENE stock on CNBC
ETFs with the largest estimated holdings in GENE
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view GENE Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.